Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui et al

Nadia E Bonekamp; Roberta Caorsi; Joost Frenkel; Marco Gattorno

doi:10.1136/annrheumdis-2017-212832

Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui et al

Nadia E Bonekamp
, Roberta Caorsi
, Joost Frenkel
, Marco Gattorno

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Article number	e89
Journal	Annals of the Rheumatic Diseases
Volume	77
Issue number	12
DOIs	https://doi.org/10.1136/annrheumdis-2017-212832
Publication status	Published - Nov 2018

Keywords

fever syndromes
inflammation
treatment

Access to Document

10.1136/annrheumdis-2017-212832

Cite this

@article{587c3a27a8304052a74085a6e2d91820,

title = "Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui et al",

keywords = "fever syndromes, inflammation, treatment",

author = "Bonekamp, \{Nadia E\} and Roberta Caorsi and Joost Frenkel and Marco Gattorno",

year = "2018",

month = nov,

doi = "10.1136/annrheumdis-2017-212832",

language = "English",

volume = "77",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui et al

AU - Bonekamp, Nadia E

AU - Caorsi, Roberta

AU - Frenkel, Joost

AU - Gattorno, Marco

PY - 2018/11

Y1 - 2018/11

KW - fever syndromes

KW - inflammation

KW - treatment

UR - https://www.scopus.com/pages/publications/85049004341

U2 - 10.1136/annrheumdis-2017-212832

DO - 10.1136/annrheumdis-2017-212832

M3 - Comment/Letter to the editor

C2 - 29331963

SN - 0003-4967

VL - 77

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 12

M1 - e89

ER -

Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui et al

Keywords

Access to Document

Other files and links

Cite this